To stabilize this condition we started rituximab therapy immediately after the third cycle of immunoadsorption, with 375 mg/m 2 rituximab being administered intravenously once weekly for 4 weeks.

Approval follows results from the Phase III ECHO trial, which demonstrated that Calquence plus chemotherapy reduced the risk ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

The Food and Drug Administration (FDA) has approved Calquence ® (acalabrutinib) in combination with bendamustine and rituximab for the treatment of adults with previously untreated mantle cell ...

Celltrion’s biosimilar marketing strategy in Europe has got seriously confusing after the firm asked to market its rituximab near-copy under four different brands. Its biosimilar of Roche’s ...

The FDA has approved Genentech’s subcutaneous version of the cancer drug rituximab, allowing for a more convenient injection lasting minutes, rather than several hours. Branded as Rituxan Hycela ...

Discover how exercise enhances cancer treatment effectiveness, boosts immunity, and improves patient outcomes with ...